Navigation Links
WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks
Date:8/27/2009

SALEM, N.H., Aug. 27 /PRNewswire/ -- AgaMatrix, Inc., the makers of WaveSense blood glucose meters, announced today their continued commitment to educate health care professionals and patients on the importance of blood glucose meter (BGM) accuracy for all patients. WaveSense BGM's uniquely employ WaveSense technology which personalizes each test to provide world class accuracy. They detect and correct for errors caused by different environmental conditions and blood samples.

According to an industry whitepaper, nearly 90,000 people use drugs or solutions(1), which put them at risk of death if they use some BGM's that use different technology and give inaccurate results because they use the enzyme system GDH PQQ (glucose dehydrogenase pyrroloquinoline quinine). All WaveSense BGM's employ a unique, patented technology, including a different enzyme, thus are not affected by this issue.

Products representing over 30% of the BGM market could be affected(2), spanning 18 different brands. The FDA has developed a complete list of these products: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm177189.htm

Nancy D'Hondt, RPh, CDE, a nationally recognized diabetes expert from St. John Hospital and Medical Center states, "Patients with diabetes should not be put at risk by using meters that could render inaccurate results. Our patients often cannot remember which medications they take, let alone understand meter technology and capabilities. In emergency situations and in the healthcare setting, we rely more and more on accuracy and reliability using point-of-care testing devices, so eliminating the potential for error is a must, especially given that safer alternatives exist."

Clinical data shows that WaveSense brand BGM's are unaffected by maltose concentrations up to 120 mg/dL, twice the clinically relevant levels associated with peritoneal dialysis, according to Meg Wiley, Director of Clinical Affairs at AgaMatrix, makers of WaveSense diabetes products.

Falsely elevated blood glucose readings could occur when testing with BGM's that use GDH PQQ. Several drugs and solutions (including OCTAGAM(R), Extraneal(R), D-Xylose USP(R)) used in peritoneal kidney dialysis or to treat immune deficiency diseases contain, or produce as a metabolite, sugars such as maltose, xylose, or galactose that react with GDH PQQ to provide results that are higher than the patient's actual glucose level. This could result in unsafe treatment and consequent health risks.(3),(4)

About WaveSense Products:

WaveSense(TM) is a line of blood glucose meters, strips, and software designed to improve the quality of diabetes care by using a new technology that personalizes each test to provide world class accuracy. It detects and corrects for many errors caused by differences in blood samples and environmental conditions. Current AgaMatrix products include the WaveSense KeyNote(TM), Presto(TM), Jazz(TM), and the WaveSense Diabetes Manager iPhone App. WaveSense meters and strips are covered by insurance and available by mail order and at popular retail outlets such as Wal-Mart and Kroger. For more information, go to: www.wavesense.info.

(C) 2002-2009 AgaMatrix, Inc. WaveSense, KeyNote, Presto, Jazz, WaveSense Diabetes Manager are trademarks of AgaMatrix, Inc. iPhone, Wal-Mart and Kroger are registered trademarks of their respective owners.

(1) Industry whitepaper "Blood Glucose Monitoring: The Facts about System Limitations."

(2) IVD market data, BBC Whole Blood Glucose Monitoring Report (2008)

(3) FDA: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm177189.htm

(4) FDA: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm154213.htm


'/>"/>
SOURCE AgaMatrix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests
2. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
5. Diabetes Gene Raises Odds of Lower Birth Weight
6. S.C. Medical Home Pilot for Diabetes Enrolls 1,110
7. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
8. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
9. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
10. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
11. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- The Pharmaceutical Care Management Association (PCMA) today released the ... out-of-pocket spending: According to ... average amount spent out-of-pocket for drugs continues to decline, ... down from 23% in 2006. Rising ... problem. Health plans don,t have unlimited funds to pay ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology:
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical ... of the company’s executive management team with prominent executives from both inside and outside ... Chief Operating Officer, Ted Dumbauld , who has more than twenty years of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... scientific laboratories. The assembly protocols involve many repetitive steps and often scientists require ... which enables the high-throughput needed, and results in a lower error rate and ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... ... ... the eastern suburbs and South Hills of Pittsburgh now have easier access ... western Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes ...
Breaking Medicine News(10 mins):